Search

Your search keyword '"Santilli D"' showing total 155 results
Start Over Author "Santilli D"
155 results on '"Santilli D"'

1. POS0604 JAKi’S SURVIVAL RATE AND PREDICTORS OF DISCONTINUATION IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS

Author

Larosa, M., primary, Becciolini, A., additional, Parisi, S., additional, Donato, E. DI, additional, Camellino, D., additional, Adorni, G., additional, Lucchini, G., additional, Santilli, D., additional, Fusaro, E., additional, Ditto, M. C., additional, Lo Gullo, A., additional, Paroli, M., additional, Caccavale, R., additional, Volpe, A., additional, Marchetta, A., additional, Raffeiner, B., additional, Celletti, E., additional, Penta, M. DI, additional, Sabatini, E., additional, Cipollone, F., additional, Reta, M., additional, Addimanda, O., additional, Magnani, M., additional, Visalli, E., additional, Foti, R., additional, Amato, G., additional, De Lucia, F., additional, Farina, A., additional, Girelli, F., additional, Bernardi, S., additional, Colina, M., additional, Andracco, R., additional, Mansueto, N., additional, Ferrero, G., additional, Del Medico, P., additional, Molica Colella, A., additional, Franchina, V., additional, Molica Colella, F., additional, Lumetti, F., additional, Sandri, G., additional, Salvarani, C., additional, Giuggioli, D., additional, Priora, M., additional, Serale, F., additional, Ianniello, A., additional, Nucera, V., additional, Ometto, F., additional, Giampietro, C., additional, Bravi, E., additional, Platè, I., additional, Arrigoni, E., additional, Mascella, F., additional, Focherini, M. C., additional, Bezzi, A., additional, Scolieri, P., additional, Bruzzese, V., additional, Ravagnani, V., additional, Rovera, G., additional, Fiorenza, A., additional, Vitetta, R., additional, and Ariani, A., additional

Published
2024
Full Text
View/download PDF

2. AB0595 DIFFERENCES BETWEEN SELECTIVE AND UNSELECTIVE JAKi: RESULTS FROM A MULTICENTRIC, REAL LIFE STUDY CARRIED OUT ON PATIENTS WITH RA

Author

Larosa, M., primary, Camellino, D., additional, Becciolini, A., additional, Donato, E. DI, additional, Adorni, G., additional, Lucchini, G., additional, Santilli, D., additional, Arrigoni, E., additional, Bravi, E., additional, Platè, I., additional, Bezzi, A., additional, Focherini, M. C., additional, Mascella, F., additional, Bruzzese, V., additional, Scolieri, P., additional, Parisi, S., additional, Ditto, M. C., additional, Fusaro, E., additional, Ravagnani, V., additional, Rovera, G., additional, Fiorenza, A., additional, Vitetta, R., additional, Marchetta, A., additional, Volpe, A., additional, Raffeiner, B., additional, Celletti, E., additional, Penta, M. DI, additional, Sabatini, E., additional, Cipollone, F., additional, Ometto, F., additional, Giampietro, C., additional, Nucera, V., additional, Ianniello, A., additional, Serale, F., additional, Priora, M., additional, Giuggioli, D., additional, Salvarani, C., additional, Sandri, G., additional, Lumetti, F., additional, Molica Colella, F., additional, Franchina, V., additional, Molica Colella, A., additional, Del Medico, P., additional, Caccavale, R., additional, Paroli, M., additional, Ferrero, G., additional, Mansueto, N., additional, Andracco, R., additional, Colina, M., additional, Bernardi, S., additional, Girelli, F., additional, Farina, A., additional, Foti, R., additional, De Lucia, F., additional, Amato, G., additional, Lo Gullo, A., additional, Magnani, M., additional, Addimanda, O., additional, Reta, M., additional, and Ariani, A., additional

Published
2024
Full Text
View/download PDF

3. Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study

Author

Parisi, S, Becciolini, A, Ditto, M, Rozza, D, Zanetti, A, Lagana, A, Peroni, C, Centanaro Di Vittorio, C, Degiovanni, R, Realmuto, C, Scire, C, Priora, M, Di Donato, E, Santilli, D, Mozzani, F, Lucchini, G, Ariani, A, Gardelli, L, Girelli, F, Arrigoni, E, Plate, I, Bravi, E, Paroli, M, Caccavale, R, Salvarani, C, Sandri, G, Lumetti, F, Volpe, A, Marchetta, A, Fusaro, E, Parisi S., Becciolini A., Ditto M. C., Rozza D., Zanetti A., Lagana A., Peroni C. L., Centanaro Di Vittorio C., Degiovanni R., Realmuto C., Scire C. A., Priora M., Di Donato E., Santilli D., Mozzani F., Lucchini G., Ariani A., Gardelli L., Girelli F., Arrigoni E., Plate I., Bravi E., Paroli M., Caccavale R., Salvarani C., Sandri G., Lumetti F., Volpe A., Marchetta A., Fusaro E., Parisi, S, Becciolini, A, Ditto, M, Rozza, D, Zanetti, A, Lagana, A, Peroni, C, Centanaro Di Vittorio, C, Degiovanni, R, Realmuto, C, Scire, C, Priora, M, Di Donato, E, Santilli, D, Mozzani, F, Lucchini, G, Ariani, A, Gardelli, L, Girelli, F, Arrigoni, E, Plate, I, Bravi, E, Paroli, M, Caccavale, R, Salvarani, C, Sandri, G, Lumetti, F, Volpe, A, Marchetta, A, Fusaro, E, Parisi S., Becciolini A., Ditto M. C., Rozza D., Zanetti A., Lagana A., Peroni C. L., Centanaro Di Vittorio C., Degiovanni R., Realmuto C., Scire C. A., Priora M., Di Donato E., Santilli D., Mozzani F., Lucchini G., Ariani A., Gardelli L., Girelli F., Arrigoni E., Plate I., Bravi E., Paroli M., Caccavale R., Salvarani C., Sandri G., Lumetti F., Volpe A., Marchetta A., and Fusaro E.

Abstract

We evaluated the 3-year drug survival and efficacy of the biosimilar SB4/Benepali in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients, pre-viously treated with etanercept (ETA). Drug survival rate was calculated using the Kaplan–Meier method and Cox proportional hazard models were developed to examine predictors of SB4 discontin-uation. 236 patients (120 RA, 80 PsA and 36 AS), aged 60.7 ± 13.8 years and with an ETA duration of 4.1 ± 3.4 years were included. The 3-year retention rate for SB4 was 94.4%, 88% and 86% in AS, RA and PsA patients, respectively, with no difference between groups. Patients without comorbid disease had higher retention rates vs. patients with comorbid disease (90% vs. 60%, p < 0.0001). Disease activity, as measured by DAS28, DAPSA and BASDAI remained stable over the 3 years. Comorbid disease (hazard ratio; HR: 4.06, p < 0.0001) and HAQ at baseline (HR: 2.42, p = 0.0024) significantly increased the risk of SB4 discontinuation, while previous ETA duration was negatively associated with SB4 discontinuation (HR: 0.97, p = 0.0064). Forty-one (17.4%) patients left the study due to the interruption of the SB4 treatment, 31 (75.6%) discontinued due to inefficacy and 10 (24.4%) due to adverse events. This real-life study confirms the similar efficacy profile of ETA with long-term retention and a good safety profile in inflammatory arthritis patients.

Published
2022

4. AB1114 MUSCULOSKELETAL ULTRASOUND BASELINE ASSESSMENT IMPROVES THE RESPONSE TO APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A MULTICENTER STUDY

Author

Farina, A., primary, Del Medico, P., additional, Becciolini, A., additional, Lumetti, F., additional, Visalli, E., additional, Molica Colella, F., additional, Mansueto, N., additional, Platé, I., additional, Colina, M., additional, Lucchini, G., additional, Di Donato, E., additional, Santilli, D., additional, Parisi, S., additional, Ditto, M. C., additional, Fusaro, E., additional, Amato, G., additional, De Lucia, F., additional, Foti, R., additional, Molica Colella, A., additional, Franchina, V., additional, Caccavale, R., additional, Paroli, M., additional, Scolieri, P., additional, Andracco, R., additional, Bruzzese, V., additional, Gardelli, L., additional, Ferrero, G., additional, Bravi, E., additional, Arrigoni, E., additional, Girelli, F., additional, Marchetta, A., additional, Volpe, A., additional, Ianniello, A., additional, Nucera, V., additional, Sandri, G., additional, Salvarani, C., additional, and Ariani, A., additional

Published
2023
Full Text
View/download PDF

5. AB1101 THERAPEUTIC EFFECTS OF APREMILAST ON ENTHESITIS AND DACTYLITIS IN REAL CLINICAL SETTING: AN ITALIAN MULTICENTER STUDY

Author

Lo Gullo, A., primary, Becciolini, A., additional, Parisi, S., additional, Del Medico, P., additional, Farina, A., additional, Visalli, E., additional, Molica Colella, A., additional, Lumetti, F., additional, Caccavale, R., additional, Scolieri, P., additional, Andracco, R., additional, Girelli, F., additional, Bravi, E., additional, Colina, M., additional, Volpe, A., additional, Ianniello, A., additional, Ditto, M. C., additional, Nucera, V., additional, Franchina, V., additional, Platé, I., additional, DI Donato, E., additional, Amato, G., additional, Salvarani, C., additional, Gardelli, L., additional, Lucchini, G., additional, De Lucia, F., additional, Molica Colella, F., additional, Santilli, D., additional, Mansueto, N., additional, Ferrero, G., additional, Marchetta, A., additional, Arrigoni, E., additional, Foti, R., additional, Sandri, G., additional, Bruzzese, V., additional, Paroli, M., additional, Fusaro, E., additional, and Ariani, A., additional

Published
2023
Full Text
View/download PDF

6. AB0452 SURVIVAL RATE OF BARICITINIB IN A LARGE COHORT OF RHEUMATOID ARTHRITIS PATIENTS: ANALYSIS OF REAL-WORLD DATA

Author

Parisi, S., primary, Becciolini, A., additional, Ditto, M. C., additional, Del Medico, P., additional, Farina, A., additional, Visalli, E., additional, Molica Colella, A., additional, Lumetti, F., additional, Caccavale, R., additional, Scolieri, P., additional, Andracco, R., additional, Girelli, F., additional, Bravi, E., additional, Colina, M., additional, Volpe, A., additional, Ianniello, A., additional, Nucera, V., additional, Franchina, V., additional, Platé, I., additional, DI Donato, E., additional, Amato, G., additional, Salvarani, C., additional, Gardelli, L., additional, Lucchini, G., additional, De Lucia, F., additional, Molica Colella, F., additional, Priora, M., additional, Santilli, D., additional, Mansueto, N., additional, Ferrero, G., additional, Rovera, G., additional, Fiorenza, A., additional, Vitetta, R., additional, Marchetta, A., additional, Ravagnani, V., additional, Paroli, M., additional, Bernardi, S., additional, Arrigoni, E., additional, Foti, R., additional, Sandri, G., additional, Bruzzese, V., additional, Ometto, F., additional, Bezzi, A., additional, Focherini, M. C., additional, Adorni, G., additional, Mascella, F., additional, Lo Gullo, A., additional, Bianchi, G., additional, Camellino, D., additional, Larosa, M., additional, Addimanda, O., additional, Reta, M., additional, Ariani, A., additional, and Fusaro, E., additional

Published
2023
Full Text
View/download PDF

7. AB0481 UPADICITINIB EFFECTIVENESS IN RHEUMATOID ARTHRITIS: OBSERVATION FROM AN ITALIAN MULTI-CENTRIC COHORT

Author

Scolieri, P., primary, Bruzzese, V., additional, Larosa, M., additional, Farina, A., additional, Becciolini, A., additional, Lo Gullo, A., additional, Girelli, F., additional, Parisi, S., additional, Bernardi, S., additional, DI Donato, E., additional, Sandri, G., additional, Salvarani, C., additional, Bianchi, G., additional, Camellino, D., additional, Lumetti, F., additional, Del Medico, P., additional, Colina, M., additional, Bravi, E., additional, Platè, I., additional, Arrigoni, E., additional, Priora, M., additional, De Lucia, F., additional, Visalli, E., additional, Foti, R., additional, Amato, G., additional, Paroli, M., additional, Caccavale, R., additional, Andracco, R., additional, Mansueto, N., additional, Ferrero, G., additional, Molica Colella, F., additional, Franchina, V., additional, Ditto, M. C., additional, Marchetta, A., additional, Santilli, D., additional, Volpe, A., additional, Ianniello, A., additional, Nucera, V., additional, Molica Colella, A., additional, Vitetta, R., additional, Fiorenza, A., additional, Lucchini, G., additional, Adorni, G., additional, Bezzi, A., additional, Focherini, M. C., additional, Mascella, F., additional, Ravagnani, V., additional, Ometto, F., additional, Fusaro, E., additional, and Ariani, A., additional

Published
2023
Full Text
View/download PDF

8. Definition of fibromyalgia severity: Findings from a cross-sectional survey of 2339 Italian patients

Author

Salaffi, F., Di Carlo, M., Bazzichi, L., Atzeni, F., Govoni, M., Biasi, G., Di Franco, M., Mozzani, F., Gremese, E., Dagna, L., Batticciotto, A., Fischetti, F., Giacomelli, R., Guiducci, S., Guggino, G., Bentivegna, M., Gerli, R., Salvarani, C., Bajocchi, G., Ghini, M., Iannone, F., Giorgi, V., Farah, S., Cirillo, M., Bonazza, S., Barbagli, S., Gioia, C., Santilli, D., Capacci, A., Cavalli, G., Carubbi, F., Nacci, F., Riccucci, I., Sinigaglia, L., Masullo, M., Polizzi, B. M., Cutolo, M., Sarzi-Puttini, P., Gremese E. (ORCID:0000-0002-2248-1058), Bentivegna M., Santilli D., Cavalli G. (ORCID:0000-0003-1968-8987), Masullo M., Salaffi, F., Di Carlo, M., Bazzichi, L., Atzeni, F., Govoni, M., Biasi, G., Di Franco, M., Mozzani, F., Gremese, E., Dagna, L., Batticciotto, A., Fischetti, F., Giacomelli, R., Guiducci, S., Guggino, G., Bentivegna, M., Gerli, R., Salvarani, C., Bajocchi, G., Ghini, M., Iannone, F., Giorgi, V., Farah, S., Cirillo, M., Bonazza, S., Barbagli, S., Gioia, C., Santilli, D., Capacci, A., Cavalli, G., Carubbi, F., Nacci, F., Riccucci, I., Sinigaglia, L., Masullo, M., Polizzi, B. M., Cutolo, M., Sarzi-Puttini, P., Gremese E. (ORCID:0000-0002-2248-1058), Bentivegna M., Santilli D., Cavalli G. (ORCID:0000-0003-1968-8987), and Masullo M.

Abstract

Objective: To establish optimal cut-off values for the scores of the revised Fibromyalgia Impact Questionnaire (FIQR), the modified Fibromialgia Assessment Scale (FAS 2019mod), and the Polysymptomatic Distress Scale (PDS) in order to distinguish five levels of FM disease severity. Methods: Consecutive FM patients were evaluated with the three clinimetric indices, and each patient was required to answer the anchor question: 'In general, would you say your health is 1 = very good, 2 = good, 3 = fair, 4 = poor, or 5 = very poor?'-which represented the external criterion. Cut-off points were established through the interquartile reconciliation approach. Results: The study sample consisted of 2181 women (93.2%) and 158 men (6.8%), with a mean age of 51.9 (11.5) years, and mean disease duration was 7.3 (6.9) years. The overall median FIQR, FAS 2019 mod and PDS scores (25th-75th percentiles) were respectively 61.16 (41.16-77.00), 27.00 (19.00-32.00) and 19.0 (13.00-24.00). Reconciliation of the mean 75th and 25th percentiles of adjacent categories defined the severity states for FIQR: 0-23 for remission, 24-40 for mild disease, 41-63 for moderate disease, 64-82 for severe disease and >83 for very severe disease; FAS 2019 mod: 0-12 for remission, 13-20 for mild disease, 21-28 for moderate disease, 29-33 for severe disease and >33 for very severe disease; PDS: 0-5 for remission, 6-15 for mild disease, 16-20 for moderate disease, 21-25 for severe disease and >25 for very severe disease. Conclusions: Disease severity cut-offs can represent an important improvement in interpreting FM.

Published
2021

9. POS1027 APREMILAST EFFICACY IN REAL WORLD SETTINGS: RESULTS FROM AN ITALIAN MULTI-CENTER OBSERVATIONAL STUDY.

Author

Ariani, A., primary, Parisi, S., additional, Del Medico, P., additional, Farina, A., additional, Visalli, E., additional, Molica Colella, A., additional, Lumetti, F., additional, Caccavale, R., additional, Scolieri, P., additional, Andracco, R., additional, Girelli, F., additional, Bravi, E., additional, Colina, M., additional, Franchina, V., additional, Platé, I., additional, DI Donato, E., additional, Amato, G., additional, Salvarani, C., additional, De Lucia, F., additional, Santilli, D., additional, Arrigoni, E., additional, Mozzani, F., additional, Foti, R., additional, Sandri, G., additional, Bruzzese, V., additional, Paroli, M., additional, Fusaro, E., additional, and Becciolini, A., additional

Published
2022
Full Text
View/download PDF

11. Long-term methotrexate use in Rheumatoid Arthritis patients: real-world data from the MARTE study

Author

Serban, T., Allara, R., Azzolini, V., Bellintani, C., Belloli, L., Belai Beyene, N., Bucci, R., Caporali, R., Cappelli, A., Corbelli, V., de Gennaro, F., Fusaro, E., Giusti, A., Govoni, M., Magnani, L., Manzo, C., Romano, C., Rossini, M., Santilli, D., Savi Ola, G., Sinigaglia, L., Bianchi, G., Arnoldi, C., Arrigoni, E., Bajocchi, G., Beccaris, A., Brussino, L., Califano, E., Carlino, G., Castellana, P., Del Piano, M., Delvino, P. G., Denotti, A., Diana, P., Epis, O. M., Fava Lli, E., Foti, R., Ghiringhelli, P., Gilardi, A. G., Iagnocco, A., Idolazzi, L., Italiano, G., Lapadula, G., Lomater, C., Longhi, M., Lupo, A., Malav Olta, N., Manara, M., Marchetta, A., Marcialis, M. R., Mathieu, A., Mazzochi, D., Mosca, M., Muratore, M., Naclerio, C., Nallino, G., Nutile, G., Pendolino, M., Piccolo, S., Ricioppo, A., Romeo, N., Rossini, T., Salvatore, S., Sambataro, A., Sangari, D., Santo, L., Selmi, C. F., Semeraro, A., Serafino, L., Tartarelli, G., Tirri, E., Todoerti, M., Traballi, G., Tropea, S., Zizo, G., Zuccaro, C., Serban, Teodora, Allara, Roberto, Azzolini, Valeria, Bellintani, Claudio, Belloli, Laura, Belai Beyene, Nebiat, Bucci, Romano, Caporali, Roberto, Cappelli, Antonella, Corbelli, Vincenzo, DE Gennaro, Fabio, Fusaro, Enrico, Giusti, Andrea, Govoni, Marcello, Magnani, Luca, Manzo, Ciro, Romano, Ciro, Rossini, Maurizio, Santilli, Daniele, Saviola, Gianantonio, Sinigaglia, Luigi, and Bianchi, Gerolamo

Subjects
Male, rheumatoid arthritis, Time Factors, Cross-sectional study, Arthritis, Arthritis, Rheumatoid, 0302 clinical medicine, Methotrexate, Arthritis, rheumatoid, Long-term care, Citizen science, Intramuscular, Smokers, Subcutaneous, marte study, General Medicine, Postmenopause, Italy, 030220 oncology & carcinogenesis, Rheumatoid arthritis, Antirheumatic Agents, 030211 gastroenterology & hepatology, Female, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, rheumatoid, Injections, Subcutaneous, Injections, Intramuscular, methotrexate, Injections, NO, 03 medical and health sciences, Route of administration, Sex Factors, Internal medicine, medicine, Humans, Dosing, Aged, Rheumatoid, Cross-Sectional Studies, Socioeconomic Factors, rheumatoid arthritis, marte study, methotrexate, business.industry, medicine.disease, Rheumatology, Discontinuation, business
Abstract

BACKGROUND The MARTE study investigated the demographic, clinical, and therapeutic characteristics of rheumatoid arthritis (RA) patients ongoing methotrexate (MTX) treatment for longer than 8 years. METHODS This cross-sectional, observational study considered 587 RA patients from 67 Rheumatology Units across Italy. Data collected included demographic, clinical, and therapeutic characteristics, focusing on MTX prescription patterns (route of administration, dosing regimens, treatment duration, and discontinuation). RESULTS As initial therapy, 90.6% of patients received one conventional synthetic Disease Modifying Anti Rheumatic Drug (csDMARD), with treatment started within the first 3 months from diagnosis in half of the patients. MTX was the first csDMARD in 46.2% of patients. The prevalent route of administration at diagnosis was the intramuscular (60.5%), while at study entry (baseline) 57.6% were receiving subcutaneous MTX. Patients who required a higher MTX dose at study entry were those who received a significantly lower starting MTX dose (P

Published
2021

12. AB0578 SUBCLINICAL ENTHESITIS IN PSORIASIS patiEntS AS prediCtor OF ARTHRITIS (EPESCA STUDY): PRELIMINARY RESULTS

Author

Di Donato, E., primary, Becciolini, A., additional, DI Nuzzo, S., additional, Chernyschova, N., additional, Commisso, C., additional, Lamorte, S., additional, Brusasco, M., additional, Pierobon, E., additional, Santilli, D., additional, Lucchini, G., additional, Riva, M., additional, Sverzellati, N., additional, Mozzani, F., additional, and Ariani, A., additional

Published
2021
Full Text
View/download PDF

14. THU0616-HPR EXPIRATORY FLOW ACCELERATOR (EFA) IN SYSTEMIC SCLEROSIS PATIENTS WITH MUCUS HYPERSECRETION, PRODUCTIVE COUGH AND DYSPNOEA: PRELIMINARY RESULTS FROM A HOME-BASED AIRWAY CLEARANCE TECHNIQUE DAILY PROGRAM

Author

Faverzani, S., primary, Becciolini, A., additional, Crisafulli, E., additional, Nocera, F., additional, DI Donato, E., additional, Mozzani, F., additional, Riva, M., additional, Santilli, D., additional, Monica, L., additional, Barbieri, A., additional, Barone, L., additional, Marvisi, M., additional, Alfieri, V., additional, Frizzelli, A., additional, Chetta, A., additional, and Ariani, A., additional

Published
2020
Full Text
View/download PDF

15. OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSIS

Author

Ariani, A., primary, Bravi, E., additional, De Santis, M., additional, Hax, V., additional, Parisi, S., additional, Lumetti, F., additional, Girelli, F., additional, Saracco, M., additional, De Gennaro, F., additional, Giollo, A., additional, Abdel Jaber, M., additional, Bozzao, F., additional, Silva, M., additional, Ditto, M. C., additional, Lomater, C., additional, Mozzani, F., additional, Santilli, D., additional, Di Donato, E., additional, Becciolini, A., additional, Pucciarini, F., additional, Canziani, L., additional, Bodini, F. C., additional, Arrigoni, E., additional, Bredemeier, M., additional, Mendonça Da Silva Chakr, R., additional, Spinella, A., additional, Idolazzi, L., additional, Bortolotti, R., additional, Tomietto, P., additional, Baratella, E., additional, Tollot, S., additional, Giuggioli, D., additional, Fischetti, F., additional, Fusaro, E., additional, Sverzellati, N., additional, and Scirè, C. A., additional

Published
2020
Full Text
View/download PDF

16. FRI0085 RETENTION RATE OF ADALIMUMAB AND ABP 501 IN THE TREATMENT OF A LARGE COHORT OF PATIENTS WITH INFLAMMATORY ARTHRITIS: A REAL LIFE RETROSPECTIVE ANALYSIS

Author

Becciolini, A., primary, Caccavale, R., additional, Parisi, S., additional, Giordano, S., additional, Bravi, E., additional, DI Donato, E., additional, Lumetti, F., additional, Andracco, R., additional, Ditto, M. C., additional, Santilli, D., additional, Lucchini, G., additional, Volpe, A., additional, Marchetta, A., additional, Mozzani, F., additional, Sandri, G., additional, Girelli, F., additional, Arrigoni, E., additional, Fusaro, E., additional, Paroli, M., additional, and Ariani, A., additional

Published
2020
Full Text
View/download PDF

17. Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis

Author

Ariani, A, Silva, M, Seletti, V, Bravi, E, Saracco, M, Parisi, S, Gennaro, F, Idolazzi, L, Caramaschi, P, Benini, C, Bodini, F, Scire, C, Carrara, G, Lumetti, F, Alfieri, V, Bonati, E, Lucchini, G, Aiello, M, Santilli, D, Mozzani, F, Imberti, D, Michieletti, E, Arrigoni, E, Delsante, G, Pellerito, R, Fusaro, E, Chetta, A, Sverzellati, N, Ariani A., Silva M., Seletti V., Bravi E., Saracco M., Parisi S., Gennaro F. D., Idolazzi L., Caramaschi P., Benini C., Bodini F. C., Scire C. A., Carrara G., Lumetti F., Alfieri V., Bonati E., Lucchini G., Aiello M., Santilli D., Mozzani F., Imberti D., Michieletti E., Arrigoni E., Delsante G., Pellerito R., Fusaro E., Chetta A., Sverzellati N., Ariani, A, Silva, M, Seletti, V, Bravi, E, Saracco, M, Parisi, S, Gennaro, F, Idolazzi, L, Caramaschi, P, Benini, C, Bodini, F, Scire, C, Carrara, G, Lumetti, F, Alfieri, V, Bonati, E, Lucchini, G, Aiello, M, Santilli, D, Mozzani, F, Imberti, D, Michieletti, E, Arrigoni, E, Delsante, G, Pellerito, R, Fusaro, E, Chetta, A, Sverzellati, N, Ariani A., Silva M., Seletti V., Bravi E., Saracco M., Parisi S., Gennaro F. D., Idolazzi L., Caramaschi P., Benini C., Bodini F. C., Scire C. A., Carrara G., Lumetti F., Alfieri V., Bonati E., Lucchini G., Aiello M., Santilli D., Mozzani F., Imberti D., Michieletti E., Arrigoni E., Delsante G., Pellerito R., Fusaro E., Chetta A., and Sverzellati N.

Abstract

Objective. In this multicentre study, we aimed to evaluate the capacity of a computer-assisted automated QCT method to identify patients with SSc-associated interstitial lung disease (SSc-ILD) with high mortality risk according to validated composite clinical indexes (ILD-Gender, Age, Physiology index and du Bois index). Methods. Chest CT, anamnestic data and pulmonary function tests of 146 patients with SSc were retrospectively collected, and the ILD-Gender, Age, Physiology score and DuBois index were calculated. Each chest CT underwent an operator-independent quantitative assessment performed with a free medical image viewer (Horos). The correlation between clinical prediction models and QCT parameters was tested. A value of P<0.05 was considered statistically significant. Results. Most QCT parameters had a statistically different distribution in patients with diverging mortality risk according to both clinical prediction models (Plt;0.01). The cut-offs of QCT parameters were calculated by receiver operating characteristic curve analysis, and most of them could discriminate patients with different mortality risk according to clinical prediction models. Conclusion. QCT assessment of SSc-ILD can discriminate between well-defined different mortality risk categories, supporting its prognostic value. These findings, together with the operator independence, strengthen the validity and clinical usefulness of QCT for assessment of SSc-ILD.

Published
2017

20. Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients

Author

Simone Parisi, Becciolini Andrea, Ditto Maria Chiara, Alberto Lo Gullo, Larosa Maddalena, Scolieri Palma, Addimanda Olga, Reta Massimo, Marino Paroli, Caccavale Rosalba, Visalli Elisa, Foti Rosario, Amato Giorgio, De Lucia Francesco, Dal Bosco Ylenia, Foti Roberta, Farina Antonella, Girelli Francesco, Bernardi Simone, Camellino Dario, Bianchi Gerolamo, Colina Matteo, Andracco Romina, Mansueto Natalia, Ferrero Giulio, Del Medico Patrizia, Molica Colella Aldo, Franchina Veronica, Molica Colella Francesco, Lumetti Federica, Sandri Gilda, Salvarani Carlo, Priora Marta, Ianniello Aurora, Nucera Valeria, Santilli Daniele, Lucchini Gianluca, Giuditta Adorni, Di Donato Eleonora, Bravi Elena, Platè Ilaria, Arrigoni Eugenio, Bezzi Alessandra, Focherini Maria Cristina, Mascella Fabio, Bruzzese Vincenzo, Ravagnani Viviana, Fiorenza Alessia, Rovera Guido, Vitetta Rosetta, Marchetta Antonio, Volpe Alessandro, Ometto Francesca, Ariani Alarico, and Fusaro Enrico

Subjects
JAK inhibitors, tsDMARD, bDMARD, Rheumatoid arthritis, Survival rate, Baricitinib, Therapeutics. Pharmacology, RM1-950
Abstract

Objectives: The persistence in therapy of rheumatoid arthritis drugs and particularly bDMARD is a limiting factor for their long-term use. The randomized controlled trials (RCTs) may not reflect real-world contexts due to strict inclusion and exclusion criteria. Baricitinib, which targets both JAK1 and JAK2, has been used in Italy for several years. The aim of this multi-center study is to assess the real world persistence on therapy of baricitinib in RA patients and to identify predictive factors of baricitinib's survival rate. Methods: This is a retrospective, multicentric, Italian, longitudinal study. All patients were enrolled according to the following criteria: a) age ≥ 18 years old; b) diagnosed with RA according 2010 ACR/EULAR classification criteria; c) treated with baricitinib. In order to describe baricitinib clinical efficacy, the survival rate was evaluated by The Kaplan–Meier curve. Then, predictive factors of drug retention rate were assessed by performing the Cox analysis, identifying which risk factors influenced treatment persistence. Results: Overall, we included 478 patients treated with baricitinib. Among them, 380 (79.5%) were females. Baricitinib's survival rate was 94.6% at 6 months, 87.9% at 12 months, 81.7% at 24 months and 53.4% at 48 months. The Cox analysis regression showed that a higher bDMARDs/tsDMARD line of therapy seems to be a negative prognostic factor for the drug retention rate (HR 1.26 CI 95% 1.07–1.49, p = 0.006. Conclusion: Real-life study confirms baricitinib effectiveness up to 4 years, but previous treatment with bDMARDs was a negative prognostic factor for its survival rate.

Published
2024
Full Text
View/download PDF

21. Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: A multi-centric study

Author

Ariani, A, Silva, M, Bravi, E, Saracco, M, Parisi, S, De Gennaro, F, Lumetti, F, Idolazzi, L, Seletti, V, Caramaschi, P, Benini, C, Bodini, F, Scire, C, Lucchini, G, Santilli, D, Mozzani, F, Imberti, D, Arrigoni, E, Delsante, G, Pellerito, R, Fusaro, E, Sverzellati, N, Ariani A., Silva M., Bravi E., Saracco M., Parisi S., De Gennaro F., Lumetti F., Idolazzi L., Seletti V., Caramaschi P., Benini C., Bodini F. C., Scire C. A., Lucchini G., Santilli D., Mozzani F., Imberti D., Arrigoni E., Delsante G., Pellerito R., Fusaro E., Sverzellati N., Ariani, A, Silva, M, Bravi, E, Saracco, M, Parisi, S, De Gennaro, F, Lumetti, F, Idolazzi, L, Seletti, V, Caramaschi, P, Benini, C, Bodini, F, Scire, C, Lucchini, G, Santilli, D, Mozzani, F, Imberti, D, Arrigoni, E, Delsante, G, Pellerito, R, Fusaro, E, Sverzellati, N, Ariani A., Silva M., Bravi E., Saracco M., Parisi S., De Gennaro F., Lumetti F., Idolazzi L., Seletti V., Caramaschi P., Benini C., Bodini F. C., Scire C. A., Lucchini G., Santilli D., Mozzani F., Imberti D., Arrigoni E., Delsante G., Pellerito R., Fusaro E., and Sverzellati N.

Abstract

Purpose. Interstitial lung disease (ILD) related to systemic sclerosis (SSc) is assessed with pulmonary functional tests (PFTs) and semi-quantitative scores based on extent of ILD detectable on chest computed tomography (CT). CT quantitative indexes (QCTIs) are promising tools to assess extent of ILD. This study's aim is to evaluate the validity of QCTI compared with that of chest CT standard evaluation and PFTs. Moreover, QCTI differences between patients subgroups according to prognostic stratifications were investigated. Methods. ILD-SSc of patients from six rheumatological clinics was routinely assessed with chest CT and PFTs. Patients were clustered according to prognosis based on functional and/or radiological examinations. Finally, chest CTs were processed with OsiriX in order to obtain QCTI. Results. Two hundred fifty-seven SSc patients were enrolled. QCTI correlation between extent of ILD and PFTs range from - 0.60 to 0.58 and from - 0.54 to 0.52, respectively. The majority of QCTI have a different distribution in patients subgroups based on prognosis. Most of QCTI discriminate patients with an ILD severity leading to a poor prognosis. Conclusions. QCTI assessment of ILD-SSc is comparable to the evaluation based on chest CT and/or PFTs. QCTI values corresponding to severe ILD were identified. QCTIs are excellent candidates for a new and more reliable SSc-ILD assessment.

Published
2015

22. FRI0651 Quantitative chest ct predicts 8-years-mortality and comorbidity in systemic sclerosis

Author

Ariani, A., primary, Silva, M., additional, Bravi, E., additional, Saracco, M., additional, Parisi, S., additional, De Gennaro, F., additional, Idolazzi, L., additional, De Santis, M., additional, Girelli, F., additional, Lumetti, F., additional, Volpe, A., additional, Santilli, D., additional, Mozzani, F., additional, Lucchini, G., additional, Giuggioli, D., additional, Seletti, V., additional, Bacchini, E., additional, Benini, C., additional, Arrigoni, E., additional, Bodini, F. C., additional, Paolazzi, G., additional, Imberti, D., additional, Fusaro, E., additional, Scirè, C. A., additional, and Sverzellati, N., additional

Published
2018
Full Text
View/download PDF

23. Institutional Innovations and Economic Development in Lombardy, Eighteenth – Twentieth Centuries

Author

Congost, R, Gelman, J, Santos, R, Serrão, JV, Rodrigues, E, Morell, M, Locatelli, AM, Tedeschi, P, Djenderedjian, J, Santilli, D, Câmara, B, Garrido, S, Iriarte-Goñi, I, Lana, JM, Bromley, JE, Wolz, A, Locatelli, A, TEDESCHI, PAOLO, Congost, R, Gelman, J, Santos, R, Serrão, JV, Rodrigues, E, Morell, M, Locatelli, AM, Tedeschi, P, Djenderedjian, J, Santilli, D, Câmara, B, Garrido, S, Iriarte-Goñi, I, Lana, JM, Bromley, JE, Wolz, A, Locatelli, A, and TEDESCHI, PAOLO

Abstract

This chapter deals with the contribute of state-led institutional reforms in property rights since the second half of the eighteenth century to change Lombard agriculture and to accelerate economic development, which made this one of the most dynamic and productive regions deals with the contribute of state-led institutional reforms in property rights since the second half of the eighteenth century to change Lombard agriculture and to accelerate economic development, which made this one of the most dynamic and productive regions in contemporary Europe. The paper in particular focuses on a succession of reforms which began in eighteenth-century western Lombardy as a province in the Austrian empire, and which were then pursued under Napoleonic rule in the early nineteenth century and later, again under Austrian rule, generalized to the other areas of Lombardy. Reforms involved the drawing up and the successive extension and updating of a land cadastre, which made the allocation of landed property more precise and produced a quantitative assessment of its economic potential for tax purposes; the privatization of common land and collective rights; and correlative fiscal policies which had built-in incentives for landowners to either invest or sell the land to those willing to do so.

Published
2017

24. Quantitative chest CT in ILD-SSC patients with divergent risks of mortality

Author

Ariani, A., Silva, M., Seletti, V., Bravi, E., Saracco, M., Parisi, S., De Gennaro, F., Lumetti, F., Idolazzi, L., Caramaschi, P., Benini, C., Bodini, F. C., Scirè, C. A., Alfieri, V., Bonati, E., Lucchini, G., Aiello, M., Santilli, D., Mozzani, F., Imberti, D., Arrigoni, E., Delsante, G., Michieletti, E., Pellerito, R., Fusaro, E., Chetta, A. A., and Sverzellati, N.

Subjects
NO
Published
2016

28. A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility

Author

David Carmona, F, Mackie, SL, Martin, J-E, Taylor, JC, Vaglio, A, Eyre, S, Bossini-Castillo, L, Castaneda, S, Cid, MC, Hernandez-Rodriguez, J, Prieto-Gonzalez, S, Solans, R, Ramentol-Sintas, M, Francisca Gonzalez-Escribano, M, Ortiz-Fernandez, L, Morado, IC, Narvaez, J, Miranda-Filloy, JA, Beretta, L, Lunardi, C, Cimmino, MA, Gianfreda, D, Santilli, D, Ramirez, GA, Soriano, A, Muratore, F, Pazzola, G, Addimanda, O, Wijmenga, C, Witte, T, Schirmer, JH, Moosig, F, Schoenau, V, Franke, A, Palm, O, Molberg, O, Diamantopoulos, AP, Carette, S, Cuthbertson, D, Forbess, LJ, Hoffman, GS, Khalidi, NA, Koening, CL, Langford, CA, McAlear, CA, Moreland, L, Monach, PA, Pagnoux, C, Seo, P, Spiera, R, Sreih, AG, Warrington, KJ, Ytterberg, SR, Gregersen, PK, Pease, CT, Gough, A, Green, M, Hordon, L, Jarrett, S, Watts, R, Levy, S, Patel, Y, Kamath, S, Dasgupta, B, Worthington, J, Koeleman, BPC, de Bakker, PIW, Barrett, JH, Salvarani, C, Merkel, PA, Gonzalez-Gay, MA, Morgan, AW, Martin, J, Carmona, F. David, Mackie, Sarah L., Martín, Jose-Ezequiel, Taylor, John C., Vaglio, Augusto, Eyre, Stephen, Bossini-Castillo, Lara, Castañeda, Santo, Cid, Maria C., Hernández-Rodríguez, José, Prieto-González, Sergio, Solans, Roser, Ramentol-Sintas, Marc, González-Escribano, M. Francisca, Ortiz-Fernández, Lourde, Morado, Inmaculada C., Narváez, Javier, Miranda-Filloy, José A., Beretta, Lorenzo, Lunardi, Claudio, Cimmino, Marco A., Gianfreda, Davide, Santilli, Daniele, Ramirez, Giuseppe A., Soriano, Alessandra, Muratore, Francesco, Pazzola, Giulia, Addimanda, Olga, Wijmenga, Cisca, Witte, Torsten, Schirmer, Jan H., Moosig, Frank, Schönau, Verena, Franke, Andre, Palm, Oyvind, Molberg, Oyvind, Diamantopoulos, Andreas P., Carette, Simon, Cuthbertson, David, Forbess, Lindsy J., Hoffman, Gary S., Khalidi, Nader A., Koening, Curry L., Langford, Carol A., Mcalear, Carol A., Moreland, Larry, Monach, Paul A., Pagnoux, Christian, Seo, Philip, Spiera, Robert, Sreih, Antoine G., Warrington, Kenneth J., Ytterberg, Steven R., Gregersen, Peter K., Pease, Colin T., Gough, Andrew, Green, Michael, Hordon, Lesley, Jarrett, Stephen, Watts, Richard, Levy, Sarah, Patel, Yusuf, Kamath, Sanjeet, Dasgupta, Bhaskar, Worthington, Jane, Koeleman, Bobby P.C., De Bakker, Paul I.W., Barrett, Jennifer H., Salvarani, Carlo, Merkel, Peter A., González-Gay, Miguel A., Morgan, Ann W., and Martín, Javier

Subjects
Multifactorial Inheritance, Genotype, European Continental Ancestry Group, Genes, MHC Class II, Giant Cell Arteritis, Genetic Association Studie, Article, White People, MHC Class II, Cohort Studies, Genetic, Genes, Genetic Association Studies, Humans, Multivariate Analysis, Odds Ratio, Genetics, Genetics(clinical), Cohort Studie, Multivariate Analysi, Giant Cell Arteriti, Genetics (clinical), Human
Abstract

We conducted a large-scale genetic analysis on giant cell arteritis (GCA), a polygenic immune-mediated vasculitis. A case-control cohort, comprising 1,651 case subjects with GCA and 15,306 unrelated control subjects from six different countries of European ancestry, was genotyped by the Immunochip array. We also imputed HLA data with a previously validated imputation method to perform a more comprehensive analysis of this genomic region. The strongest association signals were observed in the HLA region, with rs477515 representing the highest peak (p = 4.05 × 10(-40), OR = 1.73). A multivariate model including class II amino acids of HLA-DRβ1 and HLA-DQα1 and one class I amino acid of HLA-B explained most of the HLA association with GCA, consistent with previously reported associations of classical HLA alleles like HLA-DRB1(∗)04. An omnibus test on polymorphic amino acid positions highlighted DRβ1 13 (p = 4.08 × 10(-43)) and HLA-DQα1 47 (p = 4.02 × 10(-46)), 56, and 76 (both p = 1.84 × 10(-45)) as relevant positions for disease susceptibility. Outside the HLA region, the most significant loci included PTPN22 (rs2476601, p = 1.73 × 10(-6), OR = 1.38), LRRC32 (rs10160518, p = 4.39 × 10(-6), OR = 1.20), and REL (rs115674477, p = 1.10 × 10(-5), OR = 1.63). Our study provides evidence of a strong contribution of HLA class I and II molecules to susceptibility to GCA. In the non-HLA region, we confirmed a key role for the functional PTPN22 rs2476601 variant and proposed other putative risk loci for GCA involved in Th1, Th17, and Treg cell function.

Published
2015

29. FRI0260 Quantitative CT Indexes in ILD-SSC Patients with Different Autoantibodies: Table 1

Author

Ariani, A., primary, Bravi, E., additional, Saracco, M., additional, Parisi, S., additional, De Gennaro, F., additional, Idolazzi, L., additional, Silva, M., additional, Seletti, V., additional, Lumetti, F., additional, Caramaschi, P., additional, Benini, C., additional, Bodini, F.C., additional, Scirè, C.A., additional, Lucchini, G., additional, Santilli, D., additional, Imberti, D., additional, Arrigoni, E., additional, Michieletti, E., additional, Pellerito, R., additional, Fusaro, E., additional, and Sverzellati, N., additional

Published
2016
Full Text
View/download PDF

31. AB0930 Quantitative Chest Ct in Ild-Ssc Patients with Divergent Risks of Mortality

Author

Ariani, A., primary, Silva, M., additional, Seletti, V., additional, Bravi, E., additional, Saracco, M., additional, Parisi, S., additional, De Gennaro, F., additional, Lumetti, F., additional, Idolazzi, L., additional, Caramaschi, P., additional, Benini, C., additional, Bodini, F.C., additional, Scirè, C.A., additional, Alfieri, V., additional, Bonati, E., additional, Lucchini, G., additional, Aiello, M., additional, Santilli, D., additional, Mozzani, F., additional, Imberti, D., additional, Arrigoni, E., additional, Delsante, G., additional, Michieletti, E., additional, Pellerito, R., additional, Fusaro, E., additional, Chetta, A.A., additional, and Sverzellati, N., additional

Published
2016
Full Text
View/download PDF

32. FRI0443 Can Quantitative Chest CT Predict Interstitial Lung Disease Worsening in Systemic Sclerosis? Results from a Multi-Centre Prospective Cohort Study

Author

Ariani, A., primary, Silva, M., additional, Parisi, S., additional, Saracco, M., additional, Bravi, E., additional, De Gennaro, F., additional, Benini, C., additional, Caramaschi, P., additional, Lumetti, F., additional, Seletti, V., additional, Idolazzi, L., additional, Bodini, F.C., additional, Scirè, C.A., additional, Lucchini, G., additional, Santilli, D., additional, Mozzani, F., additional, Delsante, G., additional, Imberti, D., additional, Arrigoni, E., additional, Pellerito, R., additional, Fusaro, E., additional, and Sverzellati, N., additional

Published
2015
Full Text
View/download PDF

36. Elementary Steps and Mechanisms: Sections 5.3– 5.5

Author

Kraus, M., primary, Pajonk, G. M., additional, Sachtler, W. M. H., additional, Pal, Z., additional, Somorjai, G. A., additional, Block, J. H., additional, Cocke, D. L., additional, Kruse, N., additional, Santilli, D. S., additional, Gates, B., additional, Martens, J. A., additional, Jacobs, P. A., additional, Catlow, C. R. A., additional, Bell, A. T., additional, Maginn, E. J., additional, and Theodorou, D. N., additional

Full Text
View/download PDF

37. OP0095 Comparison of Interstitial Lung Disease CT Indexes and Pulmonary Function Values in Sistemic Sclerosis Patients: A Multicenter Study

Author

Ariani, A., primary, Bravi, E., additional, Saracco, M., additional, Parisi, S., additional, De Gennaro, F., additional, Idolazzi, L., additional, Silva, M., additional, Lumetti, F., additional, Benini, C., additional, Arrigoni, E., additional, Santilli, D., additional, Fusaro, E., additional, Pellerito, R., additional, Delsante, G., additional, Bodini, F.C., additional, and Sverzellati, N., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results